AMENDMENTS TO THE CLAIMS

Please amend claims 1, 3, 9 and 10 to read as follows:

1 1.(Currently Amended) A compound, having the formula I:





2 (I)

3 where R_1 is selected from the group consisting of an alkyl group and an alkenyl group;

4 X represents



;

R_2 is selected from the group consisting of a halogen ~~(o, m, p)~~ group, $-NH_2$, $-NO_2$ and a hydrogen group;

R_3 is selected from the group consisting of a hydrogen group and a hydroxyl group~~; and~~

~~n is 0 to 2~~.

2.(Originaol) The compound of claim 1, wherein said halogen group is selected from the group consisting of F, Cl, Br, and I.

3.(Currently Amended) A pharmaceutical composition, comprising a compound having the formula I:



(I)

where R_1 is selected from the group consisting of an alkyl group and an alkenyl group;

X represents





;

R_2 is selected from the group consisting of a halogen ~~(o, m, p)~~ group, $-NH_2$, $-NO_2$ and a hydrogen group;

R_3 is selected from the group consisting of a hydrogen group and a hydroxyl group~~; and~~

~~n is 0 to 2~~.

4.(Original) The pharmaceutical composition of claim 3, wherein said halogen group is selected from the group consisting of F, Cl, Br, and I.

5.(Original) The pharmaceutical composition of claim 4, wherein said pharmaceutical

composition has α_2-adrenergic/5-HT_{2A} antagonist activity.

6.(Original) The pharmaceutical composition of claim 4, wherein said pharmaceutical composition has 5-HT re-uptake activity.

7.(Original) The pharmaceutical composition of claim 4, wherein said pharmaceutical composition has anti-oxidant activity.

8.(Original) The pharmaceutical composition of claim 4, wherein said pharmaceutical composition has α_2-adrenergic/5-HT_{2A} antagonist activity, 5-HT re-uptake activity, and anti-oxidant activity.

9.(Currently Amended) A method of manufacturing a compound having the formula I, said method comprising the steps of:

preparing ~~4-epoxy-isoeugenol~~ 4-oxy-methyloxirane-3-methoxy-1-propylenyl benzene or its derivative;

mixing phenyl piperazine dissolved in methanol with ~~the 4-epoxy isoeugenol~~ said 4-oxy-methyloxirane-3-methoxy-1-propylenyl benzene or said its derivative to reflux at 100°C for approximately 2 to approximately 6 hours;

removing the methanol from the mixture;

passing the mixture through a silica gel column chromatography after the removing step;

eluting the passed mixture with n-hexane and ethyl acetate;

drying the eluted mixture; and

crystallizing the dried mixture with methanol to obtain the compound having the formula I:





(I)

where R_1 is selected from the group consisting of an alkyl group and an alkenyl group;

X represents



;

R_2 is selected from the group consisting of a halogen ~~(o, m, p)~~ group, $-NH_2$, $-NO_2$ and a hydrogen group;

R_3 is selected from the group consisting of a hydrogen group and a hydroxyl group~~; and~~

~~n is 0 to 2~~.

10.(Currently Amended) The method of claim 9, wherein ~~the preparing step~~ said 4-epoxy isoeugenol is prepared by a process comprising ~~comprises~~ the steps of:

mixing epichlorohydrin with isoeugenol and NaOH dissolved in ethanol;

boiling the mixture to reflux for 2-6 hours;

removing the ethanol from the mixture after the boiling step;

passing the mixture through a silica gel column chromatography;

eluting the mixture with n-hexane and ethyl acetate after the passing step; and

drying the eluted mixture with reduced pressure to obtain ~~4-epoxy isoeugenol~~ 4-oxy-methyloxirane-3-methoxy-1-propylenyl benzene.